Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
HOME > REGULATORY
REGULATORY
- Japan Mulls Simplifying Drug Delisting Process to Help Ensure Stable Supplies
March 19, 2024
- Japan to Work towards Ensuring Consistency in Different Clinical Trial Laws
March 19, 2024
- Japan Panel to Discuss Fate of SanBio’s Sakigake Cell Therapy amid Stalled Review
March 19, 2024
- Japan to Cap COVID Vaccine Copay at 7,000 Yen under NIP
March 18, 2024
- Japan to Present Class-by-Class Generic Shares to Hit New Goals: Minister
March 18, 2024
- Another Daiichi Sankyo Veteran to Take Over as Provost of SCARDA
March 15, 2024
- Japan Begins Discussions on RSV Vaccines for National Immunization Program
March 15, 2024
- Japan to Set Value-Based Share of 65% as Secondary Target for Generic Use
March 15, 2024
- Xocova Set for Renewed Price-Setting after Full Approval, Big Cut Unlikely
March 14, 2024
- PD-1/PD-L1, JAK Drugs to Be Exempt from Spillover Price Cuts: Chuikyo
March 14, 2024
- CellCept, Paraplatin Now Eligible for Health Coverage
March 14, 2024
- LEO Pharma’s Eczema Drug Adtralza OK’ed for Self-Injection
March 14, 2024
- Lagevrio, Kerendia Braced for Price Cuts after Cost-Effectiveness Assessment
March 14, 2024
- Disclosure Guidelines on Generic Supply Info Up for Public Comments
March 13, 2024
- Japan Needs Systemic Reform to Balance Universal Coverage and Access to Pricey Meds: LDP Health Affairs Chief
March 13, 2024
- English Versions of MHLW Biosimilar Trial Guidance, Q&As Now Available
March 13, 2024
- Japan to Simplify Screening for Third-Party Use of Highly Anonymous NDB Data
March 11, 2024
- Consolidate IRBs to Streamline Clinical Trials in Japan: Govt Working Group
March 11, 2024
- Japanese Health Minister Cautions Public on Multiple Measles Outbreaks
March 11, 2024
- PMDA Looks to Rev Up Pediatric and Orphan Drug Initiatives in Next 5-Year Plan: Chief
March 11, 2024
ページ
Your reputation as an employer matters.A survey completed by Indeed found that 95% of job seekers found a company’s reputation was an important consideration.When top talent is a scarce commodity, companies need to do more than just make an offer.…
A health ministry panel on pharmaceutical regulations on December 13 discussed the need for confirmatory trial data in Japanese subjects for drugs to treat ultra-rare diseases. The industry proposed waving the implementation of Japanese studies when deemed appropriate in a…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…